

中国肿瘤生物治疗杂志

CHINESE J 0 I



首页 期刊概况 编委会 期刊内容 特邀审稿 投稿指南 出版发行

383~388.乳腺癌特异性多肽介导的HSV-TK/GCV系统的构建及其靶向杀伤效应[J].耿计伟,董坚,刘为青,高嫦娥,熊秋霞,缪延栋,周华华,李秋恬,李臣.中国肿瘤生物治疗杂志,2011,18(4)

乳腺癌特异性多肽介导的HSV-TK/GCV系统的构建及其靶向杀伤效应 点此下载全文

耿计伟 董坚 刘为青 高嫦娥 熊秋霞 缪延栋 周华华 李秋恬 李臣

昆明医学院 第一附属医院 生物治疗中心,云南 昆明 650032;昆明医学院 第一附属医院 生物治疗中心,云南 昆明 650032;

基金项目: 国家自然科学基金资助项目(No. 3086033);云南省应用基础研究重点项目资助(No. 2009CC023);云南省科技基础条件平台建设项目资助(No. 2007DA006)

DOI:

摘要:

目的: 研究乳腺癌MDA-MB-231细胞特异性转导多肽PI介导的HSV-TK/GCV抗瘤系统对乳腺癌MDA-MB-231细胞的体外靶向杀伤作用。 方法: 以PCR从质粒p ORF-HSV-TK中扩增目的基因PI-TK,克隆到原核表达载体pET-28a(+)中,构建pET-28a(+)-PI-TK载体,转化宿主菌,经IPTG诱导表达PI-TK融合蛋白,利用His-Tag对其进行纯化,SDS-PAGE和Western blotting鉴定PI-TK融合蛋白。将不同质量浓度的PI-TK融合蛋白与MDA-MB-231细胞共培养,联合更昔洛韦(gancicl ovier,GCV)作用后,倒置显微镜下观察细胞的形态变化,CCK-8法检测MDA-MB-231细胞的增殖。 结果: 成功构建了重组原核表达载体pET-28a(+)-PI-TK,获得纯化的PI-TK融合蛋白,SDS-PAGE及Western blotting鉴定PI-TK融合蛋白表达正确。单独PI-TK融合蛋白不影响MDA-MB-231细胞的形态和增殖,但PI-TK融合蛋白表达正确。单独PI-TK融合蛋白不影响MDA-MB-231细胞的形态和增殖,但PI-TK融合蛋白表达正确。单处PI-TK融合蛋白不影响MDA-MB-231细胞的形态和增殖,但PI-TK融合医231细胞的IC 50值为152.64 μg/ml。上述各作用对MDA-MB-435细胞均无影响(P <0.05)。 结论: 乳腺癌特异性转导多肽PI介导的HSV-TK/GCV抗瘤系统可靶向杀伤MDA-MB-231细胞

关键词: 乳腺癌特异性多肽 PI 乳腺癌 MDA-MB-231细胞 HSV-TK/GCV抗瘤系统 靶向性

Construction and targeted effects of breast cancer specific peptide-mediated HSV-TK/GCV anti-tumor system Download Fulltext

GENG Ji-wei DONG Jian LIU Wei-qing GAO Chang-e XIONG Qiu-xia MIAO Yan-dong ZHOU Hua-hua LI Qiu-tian LI Chen

Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical College, Kunming 650032, Yunnan, China; Biotherapy Center, First Affiliated Hospital of Kunming Medical Colleg

Fund Project:supported by the National Natural Science Foundation of China (No. 3086033), the Key Foundation of Applied Basic Research Program Yunnan Province (No. 2009CC023), and the Basic Platform Construction Program for Science and Technology in Yunnan Province (No. 2007DA006)

Abstract:

Objective: To investigate the targeted killing effect of breast cancer specific peptide PI-mediated HSV-TK/GCV system against human breast cancer MDA-MB-231 cells in vitro. Methods: PI-TK gene was amplified from pORF-HSV-TK plasmid by PCR, and was re-inserted into the prokaryotic expression plasmid pET-28a (+); the pET-28a (+)-PI-TK plasmid was constructed and transfected into the host bacteria. After induction with IPTG, PI-TK fusion protein was purified by His-Tag and further identified by SDS-PAGE and Western blotting analysis. MDA-MB-231 cells were cultured with different dosages of PI-TK fusion protein; after further treatment with ganciclovier (GCV), the morphology changes of MDA-MB-231 cells were observed under inverted microscope, and the cell proliferation was evaluated by CCK-8 assay. Results: Recombinant prokaryotic expression plasmid pET-28a (+)-PI-TK was successfully constructed. The purified PI-TK fusion protein was obtained and confirmed by the SDS-PAGE and Western blotting analysis. PI-TK fusion protein alone failed to affect the morphology and proliferation of MDA-MB-231 cells, but when combined with GCV, PI-TK fusion protein specifically inhibited the proliferation of MDA-MB-231 cells in a dose-dependent manner, with inhibitory rate of 200 µg/ml PI-TK + 10 mg/L GCV being (68.9±7.57)%, and IC 50 being 152.64 µg/ml, but it had no effects on MDA-MB-435 cells (P <0.05). Conclusion: The breast cancer specific peptides PI-mediated HSV-TK anti-tumor system can specifically kill MDA-MB-231 cells.

Keywords: breast cancer specific peptide breast cancer MDA-MB-231 cell HSV-TK/GCV suicide gene system targeted

查看全文 查看/发表评论 下载PDF阅读器

Copyright © Biother.Org™ All Rights Reserved 主管单位:中国科学技术协会 主办单位:中国免疫学会、中国抗癌学会地址:上海市杨浦区翔殷路800号 邮政编码: 200433 京ICP备06011393号-2本系统由北京勤云科技发展有限公司设计